White coat status is a predictive marker for post-esophageal endoscopic submucosal dissection stricture: a retrospective study.


Journal

Esophagus : official journal of the Japan Esophageal Society
ISSN: 1612-9067
Titre abrégé: Esophagus
Pays: Japan
ID NLM: 101206627

Informations de publication

Date de publication:
07 2019
Historique:
received: 08 05 2018
accepted: 05 02 2019
pubmed: 6 3 2019
medline: 21 5 2020
entrez: 6 3 2019
Statut: ppublish

Résumé

Steroid therapy is primarily used to prevent esophageal stricture after endoscopic submucosal dissection (ESD). However, esophageal stricture can still occur after preventive therapy, and the effect of preventive steroid therapy cannot be predicted before stricture formation. This study aimed to clarify the risk factors for esophageal stricture after preventive steroid therapy. This was a retrospective study conducted at three institutions. From January 2011 to February 2018, 28 large-sized SENs in 26 patients who had a mucosal defect that involved more than three-quarters of the esophageal circumference were enrolled. We classified white coats on artificial ulcers after esophageal ESD into three groups (thin, moderately thick, thick) based on endoscopic images obtained on postoperative day 7. The white coat status on the artificial ulcer after ESD was a significant risk factor for post-ESD stricture (p < 0.05). The stricture rates in patients with thin, moderately thick and thick white coats were 10.0, 36.4 and 85.7%, respectively. When thin and moderately thick white coats were combined, the stricture rate was 23.8%. The rate of stricture in lesions with thick white coats was significantly higher than that in patients with thin white coats or thin to moderately thick white coats (p < 0.05). The multivariate analysis revealed that the white coat status was an independent factor related to esophageal stricture (odds ratio 13.70, 95% confidence interval 1.22-154.0; p = 0.034). The thickness of the white coat is a useful marker for predicting the risk of post-ESD stricture and the effectiveness of preventive steroid therapy.

Sections du résumé

BACKGROUND
Steroid therapy is primarily used to prevent esophageal stricture after endoscopic submucosal dissection (ESD). However, esophageal stricture can still occur after preventive therapy, and the effect of preventive steroid therapy cannot be predicted before stricture formation. This study aimed to clarify the risk factors for esophageal stricture after preventive steroid therapy.
METHODS
This was a retrospective study conducted at three institutions. From January 2011 to February 2018, 28 large-sized SENs in 26 patients who had a mucosal defect that involved more than three-quarters of the esophageal circumference were enrolled. We classified white coats on artificial ulcers after esophageal ESD into three groups (thin, moderately thick, thick) based on endoscopic images obtained on postoperative day 7.
RESULTS
The white coat status on the artificial ulcer after ESD was a significant risk factor for post-ESD stricture (p < 0.05). The stricture rates in patients with thin, moderately thick and thick white coats were 10.0, 36.4 and 85.7%, respectively. When thin and moderately thick white coats were combined, the stricture rate was 23.8%. The rate of stricture in lesions with thick white coats was significantly higher than that in patients with thin white coats or thin to moderately thick white coats (p < 0.05). The multivariate analysis revealed that the white coat status was an independent factor related to esophageal stricture (odds ratio 13.70, 95% confidence interval 1.22-154.0; p = 0.034).
CONCLUSIONS
The thickness of the white coat is a useful marker for predicting the risk of post-ESD stricture and the effectiveness of preventive steroid therapy.

Identifiants

pubmed: 30835010
doi: 10.1007/s10388-019-00659-y
pii: 10.1007/s10388-019-00659-y
pmc: PMC6592961
doi:

Substances chimiques

Steroids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

258-263

Références

Gastrointest Endosc. 2003 Feb;57(2):165-9
pubmed: 12556777
Dis Esophagus. 2009;22(7):626-31
pubmed: 19302207
Endoscopy. 2009 Aug;41(8):661-5
pubmed: 19565442
Gastrointest Endosc. 2009 Nov;70(5):860-6
pubmed: 19577748
J Clin Gastroenterol. 2011 Mar;45(3):222-7
pubmed: 20861798
Endoscopy. 2010 Dec;42(12):1092-5
pubmed: 21038294
Gastrointest Endosc. 2011 Jun;73(6):1115-21
pubmed: 21492854
Dig Dis Sci. 2012 Jan;57(1):119-26
pubmed: 21842241
Gastrointest Endosc. 2011 Dec;74(6):1389-93
pubmed: 22136782
Clin Endosc. 2013 Nov;46(6):643-6
pubmed: 24340258
Endoscopy. 2014 Aug;46(8):640-4
pubmed: 24830402
World J Gastroenterol. 2014 Nov 7;20(41):15098-109
pubmed: 25386058
BMC Gastroenterol. 2015 Jan 22;15:1
pubmed: 25609176
Esophagus. 2015;12:1-30
pubmed: 25620903
World J Gastroenterol. 2015 Jun 21;21(23):7120-33
pubmed: 26109798
World J Surg. 2015 Dec;39(12):2955-64
pubmed: 26335901
Medicine (Baltimore). 2015 Sep;94(39):e1664
pubmed: 26426665

Auteurs

Keitaro Takahashi (K)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Mikihiro Fujiya (M)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan. fjym@asahikawa-med.ac.jp.

Nobuhiro Ueno (N)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Takeshi Saito (T)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Yuya Sugiyama (Y)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Yuki Murakami (Y)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Takuya Iwama (T)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Takahiro Sasaki (T)

Department of Gastroenterology, Asahikawa City Hospital, Asahikawa, Japan.

Masami Ijiri (M)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Kazuyuki Tanaka (K)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Aki Sakatani (A)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Katsuyoshi Ando (K)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Yoshiki Nomura (Y)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Shin Kashima (S)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Mitsuru Goto (M)

Department of Gastroenterology, Asahikawa Kosei General Hospital, Asahikawa, Japan.

Kentaro Moriichi (K)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Toshikatsu Okumura (T)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido, 078-8510, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH